Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma

被引:1
|
作者
Zhu, Wei-Hang [1 ,2 ]
Chen, Jie [1 ,2 ]
Huang, Run-Kai [1 ,2 ]
Zhang, Yuan [3 ]
Huang, Ze-Xuan [2 ,4 ]
Pang, Xiu-Qing [2 ,4 ]
Hu, Bo [5 ]
Yang, Yang [6 ,7 ,8 ]
Li, Xing [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Obstet, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Lab Med, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 3, Liver Transplantat Ctr, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Liver Dis Res, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
来源
THERANOSTICS | 2023年 / 13卷 / 13期
基金
中国国家自然科学基金;
关键词
Portal vein tumor thrombus; Coagulation; CD45(+) EPC; Hepatocellular carcinoma; Vascular endothelial cells; SUPPRESSOR-CELLS; FIBRINOGEN;
D O I
10.7150/thno.82907
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Hepatocellular carcinoma (HCC) is primarily characterized by a high incidence of vascular invasion. However, the specific mechanism underlying portal vein tumor thrombus (PVTT) in HCC remains unclear. As a consequence of myeloid cell developmental arrest, CD71(+) erythroid progenitor cells (EPCs) and myeloid-derived suppressor cells play important roles in HCC; however, their roles in PVTT remain unclear. Methods: The role of CD71(+) EPCs in the HCC tumor microenvironment (TME) was evaluated via morphological, RNA- sequencing, enzyme-linked immunosorbent assay, and flow cytometric analyses. Co-culture techniques were employed to assess the CD45(+) EPCs and their vascular compromising effect. Additionally, the PVTT-promoting function of CD45(+) EPCs was explored in vivo in a murine model. Results: The CD45(+) EPCs in HCC tissues exhibited increased myeloid cell features, including morphology, surface markers, transforming growth factor ( TGF)-beta generation, and gene expression, compared with those in circulation. Hence, a large proportion of CD45(+)EPCs, particularly those in TMEs, comprise erythroid-transdifferentiated myeloid cells (EDMCs). Additionally, the expression of C-C chemokine receptor type 2 (CCR2) mRNA was upregulated in CD45(+)EPCs within the TME. Tumor macrophages from HCC tissues induced substantial migration of CD45(+)EPCs in a dose-dependent manner. Meanwhile, results from immunofluorescence analyses revealed that these two cell types are positively associated in the TME and circulation. That is, EDMCs are chemoattracted by HCC macrophages mainly via CCR2 from CD45(+) EPCs in the circulation. Additionally, the expressions of FX, FVII, FGB, C4b, CFB, and CFH were elevated in CD45(+)EPCs within the TME compared with those in the spleen. The CD45(+)EPCs from the HCC TME promoted vessel endothelial cell migration and compromised tube formation through TGF-beta and FGB, respectively. Additionally, CD45(+)EPCs from the TME induced HCC cell migration. HCC macrophage-induced CD45(+)EPCs to exhibit higher levels of FX, FVII, FGB, and TGF-beta. Meanwhile, upregulation of CCAAT/enhancer binding protein beta expression induced FGB and TGF-beta generation in CD45(+)EPCs in the TME. WTAP, a major RNA m(6)A writer, stabilized FX and FVII mRNA and enhanced their nuclear export in CD45(+)EPCs from the TME. CD45(+)EPCs from the TME were positively associated with PVTT and poor prognosis. Splenectomy reduced the level of CD45(+)EPCs in the circulation and TME, as well as the incidence of microvascular invasion. The incidence of microvascular invasion increased following the transfer of HCC tissue CD45(+)EPCs to splenectomized HCC-bearing mice. Conclusions: The CD45(+)EPCs enriched in the HCC microenvironment are EDMCs, which are induced by HCC macrophages to migrate from the circulation to the TME. Subsequently, EDMCs promote PVTT by compromising the blood vessel endothelium, aggravating coagulation, and promoting HCC cell migration.
引用
收藏
页码:4316 / 4332
页数:17
相关论文
共 50 条
  • [41] Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus
    Shohei Komatsu
    Masahiro Kido
    Kaori Kuramitsu
    Daisuke Tsugawa
    Hidetoshi Gon
    Kenji Fukushima
    Takeshi Urade
    Hiroaki Yanagimoto
    Hirochika Toyama
    Takumi Fukumoto
    Journal of Gastrointestinal Surgery, 2022, 26 : 822 - 830
  • [42] Direct Radiofrequency Ablation of Portal Vein Tumor Thrombus in Continuity with Hepatocellular Carcinoma
    Thanos, Loukas
    Sotiropoulou, Evangelia
    Tanteles, Savvas
    Pomoni, Maria
    Kelekis, Dimitrios
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2010, 21 (02) : 285 - 288
  • [43] Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy
    Deng, Zhu-Jian
    Li, Le
    Teng, Yu-Xian
    Zhang, Yu-Qi
    Zhang, Yu-Xin
    Liu, Hao-Tian
    Huang, Jian-Li
    Liu, Zhen-Xiu
    Ma, Liang
    Zhong, Jian-Hong
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (01) : 147 - 158
  • [44] New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
    Yin, Jun
    Bo, Wen-Tao
    Sun, Jian
    Xiang, Xiao
    Lang, Jin-Yi
    Zhong, Jian-Hong
    Li, Le-Qun
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2017, 5 (02) : 169 - 176
  • [45] Liver transplantation for advanced hepatocellular carcinoma combined with portal vein tumor thrombus
    Wang, K.
    Feng, Q. C.
    Li, C. X.
    Li, X.
    Wu, X.
    Wu, Z.
    Han, S.
    Wang, X.
    Li, X.
    TRANSPLANTATION, 2018, 102 : 294 - 295
  • [46] STEREOTACTIC BODY RADIATION THERAPY ON PORTAL VEIN TUMOR THROMBUS OF HEPATOCELLULAR CARCINOMA
    Kwon, J. H.
    Bae, S. H.
    Rha, S. E.
    Jung, S. E.
    Choi, B. O.
    Jang, H. S.
    Jang, J. W.
    Choi, J. Y.
    Yoon, S. K.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S93 - S93
  • [47] Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus
    Peng, Shu-You
    Wang, Xu-An
    Huang, Cong-Yun
    Li, Jiang-Tao
    Hong, De-Fei
    Wang, Yi-Fang
    Xu, Bin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (40) : 4527 - 4535
  • [48] Application of cystoscope in surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus
    Li, Nan
    Wei, Xu-Biao
    Cheng, Shu-Qun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (22) : 5297 - 5300
  • [49] Prognostic factors for hepatocellular carcinoma presenting with macroscopic portal vein tumor thrombus
    Sakata, H
    Konishi, M
    Ryu, M
    Kinoshita, T
    Satake, M
    Moriyama, N
    Ochiai, T
    HEPATO-GASTROENTEROLOGY, 2004, 51 (60) : 1575 - 1580
  • [50] Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification
    Jiang-feng Xu
    Xi-yu Liu
    Shuai Wang
    Huai-xi Wen
    World Journal of Surgical Oncology, 13